Zhitong Chen

Cold atmospheric plasma discharged in water and its potential use in cancer therapy

Cold atmospheric plasma (CAP) has been emerged as a novel technology for cancer treatment. CAP can directly treat cells and tissue but such direct application is limited to skin or can be invoked as a supplement during open surgery. In this study we report indirect plasma treatment using CAP discharged in DI water using three gases as carriers (argon, helium and nitrogen). Plasma stimulated water was applied to human breast cancer cell line (MDA-MB-231). MTT assay tests showed that using argon plasma had the strongest effect on inducing apoptosis in cultured human breast cancer cells. This result is attributed to the elevated production of the reactive oxygen species and reactive nitrogen species in water in the case of argon plasma.

A Novel Micro Cold Atmospheric Plasma Device for Glioblastoma Both In Vitro and In Vivo

Cold atmospheric plasma (CAP) treatment is a rapidly expanding and emerging technology for cancer treatment. Direct CAP jet irradiation is limited to the skin and it can also be invoked as a supplement therapy during surgery as it only causes cell death in the upper three to five cell layers. However, the current cannulas from which the plasma emanates are too large for intracranial applications. To enhance efficiency and expand the applicability of the CAP method for brain tumors and reduce the gas flow rate and size of the plasma jet, a novel micro-sized CAP device (µCAP) was developed and employed to target glioblastoma tumors in the murine brain. Various plasma diagnostic techniques were applied to evaluate the physics of helium µCAP such as electron density, discharge voltage, and optical emission spectroscopy (OES). The direct and indirect effects of µCAP on glioblastoma (U87MG-RedFluc) cancer cells were investigated in vitro. The results indicate that µCAP generates short- and long-lived species and radicals (i.e., hydroxyl radical (•OH), hydrogen peroxide (H2O2), and nitrite (NO2−), etc.) with increasing tumor cell death in a dose-dependent manner. Translation of these findings to an in vivo setting demonstrates that intracranial µCAP is effective at preventing glioblastoma tumor growth in the mouse brain. The µCAP device can be safely used in mice, resulting in suppression of tumor growth. These initial observations establish the µCAP device as a potentially useful ablative therapy tool in the treatment of glioblastoma.

Treatment of gastric cancer cells with nonthermal atmospheric plasma generated in water

Nonthermal atmospheric plasma (NTAP) can be applied to living tissues and cells as a novel technology for cancer therapy. The authors report on a NTAP argon solution generated in deionized (DI) water for treating human gastric cancer cells (NCI-N87). Our findings show that the plasma generated in DI water with 30-min duration has the strongest effect on apoptosis in precultured human gastric cancer cells. This result can be attributed to the presence of reactive oxygen species (ROS) and reactive nitrogen species (RNS) produced in water during treatment. Furthermore, the data show that the elevated levels of RNS may play a more significant role than ROS in the rate of cell death.

In vitro Demonstration of Cancer Inhibiting Properties from Stratified Self-Organized Plasma-Liquid Interface

Experiments on plasma-liquid interaction and formation of thinly stratified self-organized patterns at plasma-liquid interface have revealed a nontrivial cancer-inhibiting capability of liquid media treated at self-organized interfacial patterns. A pronounced cancer suppressing activity towards at least two cancer cells, breast cancer MDA-MB-231 and human glioblastoma U87 cancer lines, was demonstrated in vitro. After a short treatment at the thinly stratified self-organized plasma-liquid interface pattern, the cancer inhibiting media demonstrate pronounced suppressing and apoptotic activities towards tumor cells. Importantly, this would have been impossible without interfacial stratification of plasma jet to thin (of several µm) current filaments, which plays a pivotal role in building up the cancer inhibition properties. Furthermore, thinly stratified, self-organized interfacial discharge is capable to efficiently control the ROS and RNS concentrations in the cancer-inhibiting media. In particular, abnormal ROS/RNS ratios are not achievable in discharges since they do not form stratified thin-filament patterns. Our findings could be tremendously important for understanding the cancer proliferation problem and hence, the potential of this approach in tackling the challenges of high cancer-induced mortality should be explored.

Synergetic effect of cold atmospheric plasma and iron oxide-based magnetic nanoparticles in lung cancer treatment

ABSTRACT Cold atmospheric plasma (CAP) is an emerging biomedical technique that shows great potential for cancer treatment. On the other hand, magnetic nanoparticles open up a wide field of possible applications in medicine. Here we seek to develop a novel dual cancer therapeutic method by integrating promising CAP and iron oxide‐based magnetic nanoparticles (MNPs), and evaluate its underlying mechanism for targeted lung cancer treatment. For this purpose, the synergistic effects of CAP and iron oxide‐based MNPs on cellular bioactivity, epidermal growth factor receptor (EGFR) expression, and EGFR downstream signaling pathways were investigated. Results showed that the effectiveness of CAP and iron oxide‐based MNPs for synergistic strongly killed activity against lung cancer cells, and significantly inhibited cell proliferation via reduction of viability and induction of apoptosis. Importantly, CAP combining with iron oxide‐based MNPs induced EGFR downregulation while CAP inhibited lung cancer cells via depressing pERK and pAKT. Translation of these findings to an in vivo setting demonstrates that CAP combining iron oxide‐based MNPs is effective at preventing xenograft tumors. Thus, the integration of CAP and iron oxide‐based MNPs provides a promising tool for the development of a new cancer treatment strategy. Graphical abstract Figure. No Caption available.